Aimei Health Technology Co., Ltd. (AFJK) · Nov 19, 2026 · Other events
Deadline extended — Deadline moved to December 6, 2027; trust balance falls to ~$2.45M after ~$10.38M redemptions
Aimei Health’s deadline extension keeps its Hera deal alive, but $10.4 million of redemptions leave only about $2.45 million in trust.
Aimei Health remains a blank-check company searching for a transaction after terminating its United Hydrogen deal in July; five days before this filing, it disclosed a non-binding letter of intent to combine with Hera Health Solutions, a drug-delivery technology company.
The extension preserves time to pursue Hera, but it is mostly runway rather than execution. Shareholders approved extending the business-combination deadline from December 6, 2026, to December 6, 2027. The direction was already telegraphed in the proxy materials and follows the newly disclosed Hera LOI, so the approval itself is not a major surprise. The LOI remains non-binding and still requires a definitive agreement, due diligence, regulatory clearances and shareholder approval.
| Figure | At filing | Before / reference |
|---|---|---|
| Business-combination deadline (Articles) | Dec. 6, 2027 | Dec. 6, 2026 |
| Public shares redeemed (EGM results) | 841,629 | 3,166,332 |
| Redemption price per share (EGM results) | $12.33 | |
| Redemption amount (EGM results) | $10.38M | |
| Trust account balance (EGM results) | $2.45M | ~$12.83M |
| Ordinary shares outstanding (EGM results) | 2,324,703 | 3,166,332 |
The larger development is the capital drain. Holders redeemed 841,629 shares for approximately $10.38 million, or roughly 27% of the shares outstanding at the record date. After paying those redemptions, the trust account is left with only about $2.45 million. 〔0〕 That leaves Aimei with more time but a much smaller funding base for completing the Hera transaction, increasing the importance of outside financing or deal terms that do not depend heavily on trust proceeds.
This keeps the transaction pathway open without making the transaction more real. Aimei has avoided an immediate liquidation deadline, but the filing does not announce a signed merger agreement, valuation, financing commitment or closing timetable. The company is buying optionality after a failed prior deal, while shareholders’ redemptions show that the remaining trust support is materially thinner.
Bottom line: The extension is necessary and preserves the Hera opportunity, but the heavy redemptions make the SPAC’s remaining capital base far less useful. The business story advances only modestly because the actual deal is still non-binding and under negotiation.
Definitive business combination agreement with Hera
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!